Evaluating the potential benefits of universal worldwide human papillomavirus vaccination

Therapy

Volumn 5, Issue 3, 2008, Pages 305-312

  Bosch, F Xavier ^a   de Sanjosé, Silvia ^a   Castellsagué, Xavier ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

Author keywords

Cervical cancer; HPV; Human papillomavirus; Prevention; Review; Vaccines

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER THERAPY; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; COST BENEFIT ANALYSIS; DEVELOPED COUNTRY; DRUG EFFICACY; EARLY DIAGNOSIS; FOLLOW UP; HEALTH CARE PLANNING; HUMAN; PAPANICOLAOU TEST; PRECANCER; PUBLIC HEALTH; RISK REDUCTION; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; SYMPTOMATOLOGY; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS;

EID: 44649116002     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.5.3.305     Document Type: Article

References (20)

1. Paavonen J, Jenkins D, Bosch FX et al.: Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369, 2161-2170 (2007).
2. The Future II Study Group: Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356, 1915-1927 (2007).
3. Garland SM, Hernandez-Avila M, Wheeler CM et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356, 1928-1943 (2007).
4. Giannini SL, Hanon E, Moris P et al.: Enhanced humoral and memory B cellular immunity using HPV16/18L1 VLP vaccine formulated with the MPL/ aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006).
5. Olsson SE, Villa LL, Costa RL et al.: Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 25(26), 4931-4939 (2007).
6. Harper DM, Franco EL, Wheeler CM et al.: Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367, 1247-1255 (2006).
7. Castellsague X, Diaz M, de Sanjose S et al.: Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 98, 303-315 (2006).
8. Castellsagué X, de Sanjosé S, Aguado T et al.: HPV and cervical cancer in the World. 2007 Report. WHO/ICO Information Centre an HPV and Cervical Cancer (HPV Information Centre). Vaccine 25(Suppl. 3), C1-C230 (2007).
9. Hildesheim A, Herrero R, Wacholder S et al.: Effect of human papillomavirus 16/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial. JAMA 298, 743-753 (2007).
10. Joura EA, Leodolter S, Hernandez-Avila M et al.: Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369(9574), 1693-1702 (2007).
11. Ferlay F, Bray F, Pisani P, Parkin DM: GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. In: IARC CancerBase No. 5 Version 2.0, IARC Press, Lyon, France (2005).
12. Kane MA, Sherris J, Coursaget P, Aguado T, Cutts F: Chapter 15: HPV vaccine use in the developing world. Vaccine 24(Suppl. 3), S132-S139 (2006).
13. Batson A, Meheus F, Brooke S: Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries. Vaccine 24(Suppl. 3), S219-S225 (2006).
14. Zimet GD, Liddon N, Rosenthal SL, Lazcano-Ponce E, Allen B: Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine 24(Suppl. 3), S201-S209 (2006).
15. Daley MF, Liddon N, Crane LA et al.: A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 118(6), 2280-2289 (2006).
16. International Agency for Research on Cancer: IARC Handbooks of Cancer Prevention. Cervix Cancer Screening. IARC Press, Lyon, France (2005).
17. Cuzick J, Mayrand MH, Ronco G, Snijders P, Wardle J: Chapter 10: New dimensions in cervical cancer screening. Vaccine 24(Suppl. 3), S90-S97 (2006).
18. Ronco G, Segnan N, Giorgi-Rossi P et al.: Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J. Natl Cancer Inst. 98, 765-774 (2006).
19. Sankaranarayanan R, Okkuru Esmy P, Rajkumar R et al.: Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 370, 398-406 (2007).
20. Franco EL, Cuzick J, Hildesheim A, de Sanjose S: Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine 24(Suppl. 3), S171-S177 (2006).